Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Capital Market Strategies LLC

Capital Market Strategies LLC reduced its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,000 shares of the pharmaceutical company’s stock after selling 38 shares during the quarter. Capital Market Strategies LLC’s holdings in Vertex Pharmaceuticals were worth $403,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Northwest Investment Counselors LLC acquired a new stake in shares of Vertex Pharmaceuticals in the third quarter valued at about $25,000. Highline Wealth Partners LLC purchased a new stake in Vertex Pharmaceuticals during the 3rd quarter valued at about $27,000. Dunhill Financial LLC raised its holdings in Vertex Pharmaceuticals by 70.6% in the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 24 shares during the last quarter. GHP Investment Advisors Inc. purchased a new position in Vertex Pharmaceuticals in the 2nd quarter worth approximately $29,000. Finally, Legacy Investment Solutions LLC acquired a new position in shares of Vertex Pharmaceuticals during the 3rd quarter worth approximately $33,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Wall Street Analysts Forecast Growth

VRTX has been the subject of several recent research reports. JPMorgan Chase & Co. reduced their price objective on Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating on the stock in a research report on Monday, December 23rd. Stifel Nicolaus lifted their price target on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a “hold” rating in a report on Monday, December 16th. Royal Bank of Canada upped their price objective on shares of Vertex Pharmaceuticals from $437.00 to $451.00 and gave the company a “sector perform” rating in a report on Tuesday, November 5th. Raymond James reaffirmed a “market perform” rating on shares of Vertex Pharmaceuticals in a research note on Thursday, October 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $480.00 price target on shares of Vertex Pharmaceuticals in a research note on Tuesday, November 5th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $494.04.

Vertex Pharmaceuticals Stock Down 1.4 %

Shares of VRTX stock traded down $5.56 during trading hours on Monday, reaching $401.55. 674,274 shares of the stock were exchanged, compared to its average volume of 999,172. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88. The business’s fifty day moving average is $455.37 and its two-hundred day moving average is $470.19. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. The firm has a market capitalization of $103.41 billion, a P/E ratio of -201.78 and a beta of 0.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.69 billion. During the same quarter in the previous year, the firm posted $3.67 earnings per share. The company’s revenue was up 11.6% compared to the same quarter last year. As a group, research analysts expect that Vertex Pharmaceuticals Incorporated will post -1.83 EPS for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.